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Summary
Background Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting injectable formulations. 
The LATTE-2 study evaluated long-acting cabotegravir plus rilpivirine for maintenance of HIV-1 viral suppression 
through 96 weeks.
Methods In this randomised, phase 2b, open-label study, treatment-naive adults infected with HIV-1 initially received 
oral cabotegravir 30 mg plus abacavir–lamivudine 600–300 mg once daily. The objective of this study was to select an 
intramuscular dosing regimen based on a comparison of the antiviral activity, tolerability, and safety of the 
two intramuscular dosing regimens relative to oral cabotegravir plus abacavir–lamivudine. After a 20-week induction 
period on oral cabotegravir plus abacavir–lamivudine, patients with viral suppression (plasma HIV-1 RNA <50 copies 
per mL) were randomly assigned (2:2:1) to intramuscular long-acting cabotegravir plus rilpivirine at 4-week intervals 
(long-acting cabotegravir 400 mg plus rilpivirine 600 mg; two 2 mL injections) or 8-week intervals (long-acting 
cabotegravir 600 mg plus rilpivirine 900 mg; two 3 mL injections) or continued oral cabotegravir plus abacavir–
lamivudine. Randomisation was computer-generated with stratification by HIV-1 RNA (<50 copies per mL, yes or no) 
during the first 12 weeks of the induction period. The primary endpoints were the proportion of patients with viral 
suppression at week 32 (as defined by the US Food and Drug Administration snapshot algorithm), protocol-defined 
virological failures, and safety events through 96 weeks. All randomly assigned patients who received at least one dose 
of study drug during the maintenance period were included in the primary efficacy and safety analyses. The primary 
analysis used a Bayesian approach to evaluate the hypothesis that the proportion with viral suppression for each long-
acting regimen is not worse than the oral regimen proportion by more than 10% (denoted comparable) according to 
a prespecified decision rule (ie, posterior probability for comparability >90%). Difference in proportions and associated 
95% CIs were supportive to the primary analysis. The trial is registered at ClinicalTrials.gov, number NCT02120352.
Findings Among 309 enrolled patients, 286 were randomly assigned to the maintenance period (115 to each of the 
4-week and 8-week groups and 56 to the oral treatment group). This study is currently ongoing. At 32 weeks following
randomisation, both long-acting regimens met primary criteria for comparability in viral suppression relative to the oral 
comparator group. Viral suppression was maintained at 32 weeks in 51 (91%) of 56 patients in the oral treatment group, 
108 (94%) of 115 patients in the 4-week group (difference 2·8% [95% CI −5·8 to 11·5] vs oral treatment), and 109 (95%)
of 115 patients in the 8-week group (difference 3·7% [−4·8 to 12·2] vs oral treatment). At week 96, viral suppression was
maintained in 47 (84%) of 56 patients receiving oral treatment, 100 (87%) of 115 patients in the 4-week group, and
108 (94%) of 115 patients in the 8-week group. Three patients (1%) experienced protocol-defined virological failure (two
in the 8-week group; one in the oral treatment group). Injection-site reactions were mild (3648 [84%] of 4360 injections)
or moderate (673 [15%] of 4360 injections) in intensity and rarely resulted in discontinuation (two [<1%] of 230 patients); 
injection-site pain was reported most frequently. Serious adverse events during maintenance were reported in 22 (10%)
of 230 patients in the intramuscular groups (4-week and 8-week groups) and seven (13%) of 56 patients in the oral
treatment group; none were drug related.
Interpretation The two-drug combination of all-injectable, long-acting cabotegravir plus rilpivirine every 4 weeks or 
every 8 weeks was as effective as daily three-drug oral therapy at maintaining HIV-1 viral suppression through 
96 weeks and was well accepted and tolerated.
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Introduction
An estimated 36·7 million individuals were living with 
HIV worldwide at the end of 2015.1 Advances in highly 
active antiretroviral therapies (ARTs) have improved 
treatment efficacy for patients with HIV, enhancing 
patient survival and quality of life.2,3 However, adherence 
to medication remains an important challenge; poor 
compliance can result in treatment failure and the 
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emergence of drug-resistant mutations.4 Long-acting 
injectable ART might provide some patients with a 
convenient approach to manage HIV infection that 
avoids daily oral dosing and the need to keep, store, and 
transport medications as they undertake their activities 
of daily living.5
Cabotegravir (GSK1265744) is an analogue of the 
integrase strand transfer inhibitor (INSTI) dolutegravir 
that exhibits subnanomolar potency and antiviral activity 
against a broad range of HIV-1 strains.6 Oral administration 
of cabotegravir once daily has exhibited acceptable safety 
and tolerability profiles, a long half-life (40 h), and few 
drug–drug interactions.7–9 Rilpivirine (TMC278) is a non-
nucleoside reverse transcriptase inhibitor (NNRTI) that is 
approved as a 25 mg once-daily oral medication for HIV-1 
treatment.10–12 In the phase 2b LATTE trial (ClinicalTrials.
gov identifier, NCT01641809), a two-drug regimen of once-
daily oral formulations of cabotegravir and rilpivirine 
demonstrated durable viral suppression in patients whose 
viral load was previously suppressed to less than 50 HIV-1 
RNA copies per mL by treatment with cabotegravir and 
two nucleoside reverse transcriptase inhibitors (NRTIs), 
providing proof of principle for a two-drug maintenance 
regimen using an INSTI and NNRTI.13
Long-acting injectable nanosuspension formulations of 
cabotegravir and rilpivirine are in clinical development.12,14 
Phase 1 clinical studies investigating long-acting 
cabotegravir and rilpivirine have shown prolonged 
exposures at least 30 days following gluteal intramuscular 
injections, enabling dosing at once-monthly or longer 
intervals.15,16 Combined administration of long-acting 
cabotegravir plus rilpivirine produced no clinically 
significant pharmacokinetic interactions, supporting 
investigation of these agents as the first-ever long-acting 
combination ART regimen.16 Here, we report the efficacy 
and safety of long-acting cabotegravir plus rilpivirine, 
given as intramuscular injections every 4 weeks or every 
8 weeks, compared with that of oral cabotegravir plus 
abacavir–lamivudine, as maintenance therapy through 
96 weeks for individuals who had achieved successful 
HIV-1 viral suppression with oral cabotegravir plus 
abacavir–lamivudine.
Research in context
Evidence before this study
To establish the background for this study, we searched PubMed 
publications on the topics of antiretroviral therapy and 
treatment adherence; long-acting injectable therapies; and the 
safety, efficacy, and pharmacokinetics of cabotegravir 
(GSK1265744) and rilpivirine using the keywords “antiretroviral 
therapy”, “treatment adherence”, “long-acting injectable 
therapies”, “cabotegravir”, “GSK1265744”, “rilpivirine”, and 
“TMC-2782”. We also located package inserts and government 
documents using internet search engines. All searches were 
updated as of March 7, 2017. A review of this literature shows an 
ongoing challenge in HIV therapy wherein suboptimal adherence 
to daily oral medication can lead to treatment failure or the 
emergence of viral resistance. To date, no long-acting injectable 
regimen is available to patients with HIV. Cabotegravir is an 
integrase strand transfer inhibitor with clinically demonstrated 
activity against the HIV-1 virus and a physiochemistry and 
pharmacokinetic profile amenable to its formulation and use as a 
long-acting agent. Rilpivirine is a non-nucleoside reverse 
transcriptase inhibitor approved as an oral agent for the 
treatment of HIV-1 infection in combination with other 
antiretrovirals; its physiochemistry is also appropriate for 
formulation as a long-acting agent. We did a randomised, 
open-label, parallel group, phase 2b study (LATTE-2) in patients 
with HIV-1 viral suppression on oral medication to evaluate the 
efficacy, safety, and tolerability of cabotegravir plus rilpivirine 
given as long-acting injections every 4 or 8 weeks, compared 
with daily oral cabotegravir taken with abacavir and lamivudine.
Added value of this study
The LATTE-2 study is the first to investigate the efficacy and 
safety of a long-acting injectable antiretroviral therapy for the 
treatment of HIV-1 infection. An option to treat HIV-1 without 
the use of daily oral medications represents a paradigm shift in 
the HIV-1 treatment landscape. The principal finding of the study 
is that among patients who were suppressed on an oral 
cabotegravir-based therapy, switching to a long-acting 
combination of cabotegravir and rilpivirine maintained 
virological suppression in 90% of patients overall through 
week 96 following 4-week or 8-week injectable administration at 
rates comparable to remaining on daily oral cabotegravir-based 
therapy. The complete week 96 dataset included here provides 
important evidence for both the durability of virological response 
and acceptability of intramuscular injections for chronic use with 
dual antiretroviral therapy in patients infected with HIV-1.
Implications of all the available evidence
To date, the class of integrase strand transfer inhibitors has 
shown a high level of virological efficacy in clinical studies, which 
has translated to global widespread successful use. The ability to 
employ one of these agents, in partnership with one other 
agent, as an effective long-acting injectable agent has the 
potential to address the challenges of adherence to daily 
medication faced by people living with HIV. The daily 
psychological burden of being discovered as HIV positive can be 
eased by less frequent or clinic-based medication dosing and 
might be a preferred option for some patients. Following the 
advent and proliferation of single-tablet regimens, which 
themselves constituted a leap forward in dosing convenience, 
long-acting injectables such as the cabotegravir plus rilpivirine 
regimen might represent the next revolution in HIV therapy by 




Study design and participants
LATTE-2 is an ongoing phase 2b, randomised, 
multicentre, open-label, non-inferiority, parallel-group 
trial, consisting of a 20-week induction period, 96-week 
maintenance period, extension period, and long-term 
follow-up period. The study was done at 50 sites in 
the USA, Canada, Spain, France, and Germany.
Patients who were HIV-1 positive, were aged 18 years or 
older, and had no more than 10 days of previous ART 
treatment, with screening HIV-1 RNA of at least 
1000 copies per mL and CD4+ T-cell counts of at least 
200 cells per mm³, were eligible for inclusion. Key 
exclusion criteria included the presence of any major 
antiretroviral resistance-associated mutation, pregnancy, 
moderate or severe hepatic impairment, clinically 
relevant hepatitis, hepatitis B infection, laboratory values 
of clinical concern, creatinine clearance less than 
50 mL/min, and a need for chronic anticoagulants.
Eligible patients received the induction period regimen 
of oral cabotegravir 30 mg plus abacavir–lamivudine 
600 mg–300 mg once daily for 20 weeks. Rilpivirine 
25 mg once daily was added 4 weeks before randomisation 
(week −4 [week 16 of the induction period]) and continued 
until the first injection visit (day 1). Patients who tolerated 
the induction period regimen and achieved plasma 
HIV-1 RNA less than 50 copies per mL at week −4 were 
eligible to enter the maintenance period at day 1 and were 
randomly assigned to receive intramuscular injections 
every 4 weeks (long-acting cabotegravir 400 mg plus 
rilpivirine 600 mg; two 2 mL injections) or every 8 weeks 
(long-acting cabotegravir 600 mg plus rilpivirine 900 mg; 
two 3 mL injections), with a provision for a 14-day dosing 
window, or to continue receiving oral cabotegravir 30 mg 
plus abacavir–lamivudine once daily for 96 weeks. Long-
acting injectable formulations contained 200 mg per mL 
of cabotegravir and 300 mg per mL of rilpivirine for 
administration as two separate intramuscular injections 
into the gluteus medius muscle at each dosing visit. Both 
4-week and 8-week dosing regimens had an initial loading 
dose of cabotegravir 800 mg (two 2 mL injections).
The study was done in accordance with the principles 
of the Declaration of Helsinki. Written informed consent 
was obtained from all participants, and the protocol was 
approved by the institutional review board of each study 
site. The authors vouch for the accuracy and completeness 
of the data and the analyses and for the fidelity of the 
study to the protocol.
Randomisation and masking
A computer-generated allocation sequence created by 
the validated software, RandALL (version 2.10;
GlaxoSmithKline, Research Triangle Park, NC, USA) was 
used to randomly assign patients at day 1, with 
stratification by HIV-1 RNA (<50 copies per mL, yes or 
no) before week −8 (ie, during the first 12 weeks of 
induction period treatment). Central randomisation, 
with blocks shared across sites, was used to conceal the 
allocation schedule and prevent selection bias.
An open-label design was used because a double-blind, 
double-dummy design would have resulted in an 
increased pill burden in all patients, a requirement for 
sham injections, elevated risk of oral ART non-adherence 
for oral comparator group patients receiving sham 
injections, limitations to patient-reported preference data 
comparing injectable and oral ART, as well as 
considerable trial design complexities.
Procedures
Planned analyses were done after all patients had 
completed weeks 32, 48, and 96 of the maintenance 
period (or discontinued earlier).
Adverse events were graded according to the Division of 
AIDS Table for Grading the Severity of Adverse and 
Pediatric Events (2009).17 Serious adverse events were 
defined as any untoward medical occurrence that resulted 
in death, was life-threatening, required hospitalisation, 
resulted in disability or incapacity, was a congenital 
anomaly or birth defect, or met predefined liver injury 
criteria. Liver stopping criteria were met when alanine 
aminotransferase values met or exceeded the upper limit 
of normal (ULN) by eight times, five times for 14 days, or 
three times with bilirubin at least two times the ULN (if 
>35% direct bilirubin, bilirubin fractionation is required).
Pharmacokinetic samples for cabotegravir and rilpivirine
were collected at day 1 and at weeks 1, 4, 8, 12, 16, 20, 24,
25, 28, 32, 36, 40, 41, 44, and 48.
Treatment satisfaction was measured using the HIV 
Treatment Satisfaction Questionnaire (HIVTSQ). The 
HIVTSQ status version (HIVTSQ[s]) was completed by 
patients at weeks –16 and –4 of the induction period and 
at day 1 (long-acting predose) and weeks 8, 32, 48, and 96 
of the maintenance period or at withdrawal.
Outcomes
The primary endpoints were the proportion of patients in 
the maintenance-exposed population (which consisted of 
randomly assigned patients who received at least one 
dose of study drug during the maintenance period) with 
HIV-1 RNA less than 50 copies per mL at maintenance 
week 32 (using the US Food and Drug Administration 
[FDA] snapshot algorithm), the proportion of patients 
with protocol-defined virological failures, and incidence 
and severity of adverse events and laboratory 
abnormalities.
Secondary endpoints evaluated the proportion of 
patients with plasma HIV-1 RNA less than 200 copies per 
mL and less than 50 copies per mL; incidence of 
treatment-emergent viral resistance; absolute values and 
change from baseline in plasma HIV-1 RNA; absolute 
values and changes from baseline in CD4+ cell counts; 
incidence of disease progression; incidence and severity 
of adverse events and laboratory abnormalities over time; 
absolute values and changes in laboratory parameters 
through the week 96 analysis; evaluation of plasma 
pharmacokinetic parameters and steady-state deter-
minations for cabotegravir and rilpivirine, as well as 
pharmacokinetic–pharmacodynamic relationships with 
safety and antiviral activity; and treatment satisfaction 
and medication adherence of participants using patient-
reported outcome questionnaires.
Protocol-defined virological failure following random-
isation was defined as having two consecutive plasma 
HIV-1 RNA measurements of at least 200 copies 
per mL. Patients who met the definition of protocol-
defined virological failure before receiving 
any cabotegravir plus rilpivirine injections were 
dis continued from the study; those who had received 
one or more injections entered a 52-week long-term 
follow-up period.
Statistical analysis
The primary analysis of the maintenance-exposed 
population used a Bayesian approach to evaluate the 
hypothesis that the proportion of patients with HIV-1 
RNA less than 50 copies per mL (FDA snapshot 
algorithm) at week 32 (and repeated at week 48) for each 
intramuscular long-acting regimen is not worse than the 
oral regimen proportion by more than 10% (denoted 
comparable). This Bayesian approach provided an 
Figure 1: Trial profile
LA=long-acting. *Multiple reasons for screening failure were reported for two patients. †310 patients were enrolled, but one patient withdrew consent after baseline 
visit procedures were done and before study treatment was initiated. ‡Two patients completed the induction period (and had day 1 assessments) but did not enter 
the maintenance period and were not randomly assigned (because of investigator discretion and lack of efficacy). §Patient experienced suspected protocol-defined 
virological failure at the time of withdrawal, which was subsequently confirmed.
115 patients received ≥1 dose of
intramuscular cabotegravir LA
plus rilpivirine LA every 8 weeks 
4 withdrew
1 adverse event
1 lack of efficacy
1 investigator discretion§
1 withdrew consent
111 ongoing at time of analysis 
(week 48)
50 ongoing at time of analysis 
(week 48)
104 ongoing at time of analysis 
(week 48)
1 withdrew consent
110 ongoing at time of analysis 
(week 96)
47 ongoing at time of analysis 
(week 96)
101 ongoing at time of analysis 
(week 96)
115 patients received ≥1 dose of
intramuscular cabotegravir LA
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estimate of the (posterior) probability that the hypothesis 
is true given the observed data and pre-trial information.18 
A Bayesian posterior probability of at least 90% was 
prespecified as the decision rule for claiming 
comparability for each comparison. To incorporate 
previous information for the oral group response rate 
based on data from the LATTE study,13 a beta (23, 2) prior 
distribution was assumed to reflect the belief that the 
oral group response rate was between 78% and 99% with 
95% confidence, and a non-informative prior distribution 
was assumed for the intramuscular response rate. 
Sample sizes of 45 patients in the oral cabotegravir plus 
abacavir–lamivudine group and 90 patients each in the 
intramuscular groups were chosen to ensure a high 
probability that a two-drug long-acting regimen with 
poor response relative to oral cabotegravir plus abacavir–
lamivudine once daily would be identified. With the 
chosen number of patients per treatment group, and 
assuming true response rates of 82% for long-acting 
intramuscular cabotegravir plus rilpivirine versus 92% 
for oral cabotegravir plus abacavir–lamivudine, there was 
a low probability of falsely concluding that long-acting 
intramuscular cabotegravir plus rilpivirine was 
comparable with oral cabotegravir plus abacavir–
lamivudine (simulated probability=0·064). Each long-
acting intramuscular regimen was evaluated against the 
oral cabotegravir plus abacavir–lamivudine regimen in 
the primary analysis; comparability in antiviral response 
rates between the two intramuscular regimens was 
assessed as a prespecified key secondary comparison. 
Normal approximation 95% CIs for the difference in the 
proportions (each long-acting intramuscular regimen vs 
oral regimen) are provided as supportive secondary 
analyses (prespecified b ut without a djustment f or 
multiple testing). These efficacy analyses used 
the maintenance-exposed population. Per-protocol 
sensitivity analyses excluding participants with 
prespecified protocol deviations were not done as fewer 
than 5% of participants had such deviations (threshold 
for conducting analysis specified i n a dvance i n the 
analysis plan).
In the snapshot analysis, participants with a last HIV-1 
RNA result less than 50 copies per mL in the analysis 
timepoint window were classified a s r esponders. 
Participants without HIV-1 RNA data at the visit of 
interest (due to missing data or discontinuation of study 
drug before analysis visit window) and patients who 
switched ART after week 4 were classified a s n on-
responders. For week 32, if a participant had no data 
within a window of –2 to +2 weeks, then an expanded 
window of –6 to +6 weeks was used. For week 48, if a 
participant had no data within a window of −2 to +6 weeks, 
then an expanded window of –6 to +6 weeks was used. 
For week 96, a window of –6 to +6 weeks was used.
Data for the maintenance and induction plus 
maintenance periods combined, respectively, are 
summarised by randomised group using the 
maintenance-exposed population, whereas data for the 
induction period and study population characteristics are 
summarised using the intention-to-treat exposed 
population (patients who received at least one study dose 
during the induction period [week −20 to day 1]).
Change from baseline (last value collected up to and 
including the date of first induction period treatment at 
week –20) in CD4+ cell count, plasma HIV-1 RNA, and 
patient-reported outcome endpoints are summarised 
using observed data with no imputation for missing data. 
Laboratory abnormalities are presented as maintenance 
period treatment emergent, which refers to graded toxic 
effects that developed or increased in intensity while on 
treatment in the maintenance period relative to the last 
recorded toxic effect up to and including the date of the 
first dose of the maintenance period treatment.
Antiretroviral plasma concentrations at the above-
mentioned timepoints following long-acting intra-
muscular cabotegravir plus rilpivirine administration 
were analysed using validated LC-MS/MS methods and 
are summarised over time using evaluable data that met 
sample collection window criteria, excluding samples 
affected by dosing errors (wrong dose) or oral bridging. 
Sampling windows for intramuscular dosing were set 
relative to the previous injection as follows: 0·5 h for 2 h 
post-dose samples; 1 day for 1-week post-injection visits; 
2 days for predose samples in the 4-week group, weeks 4 
Intramuscular 
cabotegravir LA 
plus rilpivirine LA 
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Age (years; range) 36 (19–62) 35 (20–64) 35 (19–57) 35 (19–64)
Sex
Male 109 (95%) 107 (93%) 46 (82%) 262 (92%)
Female 6 (5%) 8 (7%) 10 (18%) 24 (8%)
Ethnic origin
White 94 (82%) 93 (81%) 39 (70%) 226 (79%)
African American 
or African heritage
12 (10%) 17 (15%) 15 (27%) 44 (15%)
Other 9 (8%) 5 (4%) 2 (4%) 16 (6%)
Baseline HIV-1 RNA








≥100 000 copies per mL 28 (24%) 16 (14%) 7 (12%) 51 (18%)










Hepatitis C co-infection 5 (4%) 3 (3%) 2 (4%) 10 (3%)
NRTI during induction
Abacavir–lamivudine 107 (93%) 107 (93%) 53 (95%) 267 (93%)
Tenofovir–emtricitabine 8 (7%) 8 (7%) 3 (5%) 19 (7%)
Data are median (IQR) or n (%) unless stated otherwise. LA=long-acting. NRTI=nucleoside reverse transcriptase 
inhibitor.
Table 1: Baseline demographics and disease characteristics (maintenance-exposed population)
and 8 cabotegravir samples in the 8-week group, and 
midcycle concentrations 4 weeks post-injection in the 
8-week group; and 4 days for predose samples in the
8-week group (except for weeks 4 and 8 cabotegravir
samples, as described earlier). Sparse pharmacokinetic
sampling obtained after week 48 and through week 96 was 
not assayed as a matter of routine and therefore is not
reported. Plasma concentrations at week 48 are
summarised using geometric means and associated
95% CIs, whereas plasma concentration–time profiles are
summarised using arithmetic mean (SD). Relationships
between cabotegravir and rilpivirine trough concentrations 
at week 48 (or last available value before week 48 if no
week 48 data available) and week 48 virological failure
were explored graphically in a post-hoc analysis.
Role of the funding source
This study was funded by ViiV Healthcare and Janssen 
R&D. The funders participated in the study design, data 
gathering, analysis, and interpretation. All listed authors 
meet the criteria for authorship set forth by the 
International Committee of Medical Journal Editors. All 
authors had full access to the data and are responsible for 
the veracity and completeness of the reported data. The 
corresponding author had final responsibility for the 
decision to submit the manuscript for publication.
Results
The first patient was screened in April 28, 2014, and the 
last patient’s week 96 visit occurred in Nov 10, 2016. Of 
386 patients screened, 309 were enrolled in the study 
(figure 1). 282 (91%) patients were male, average age 
36·6 years (SD 10·4). 72 (23%) patients had a baseline 
CD4+ cell count of no more than 350 cells per mm³, and 
60 (19%) patients had a baseline HIV-1 RNA of at least 
100 000 copies per mL. Baseline characteristics were 
balanced among the three dosing groups. 
288 patients (93%) completed the 20-week induction 
period (intention-to-treat exposed). 21 patients (7%) 
discontinued treatment during the induction period 
(five withdrew consent, five for lack of efficacy, three for 
adverse events, three met predefined liver chemistry 
stopping criteria, two for protocol deviation, two were 
lost to follow-up, and one at investigator discretion). 
286 patients qualified for and entered the maintenance 
period. Patients were randomly assigned (2:2:1) to receive 
intramuscular injections of long-acting cabotegravir plus 
rilpivirine every 4 weeks (n=115; 4-week group) or every 
8 weeks (n=115; 8-week group) or continue the oral 
cabotegravir plus abacavir–lamivudine regimen (n=56; 
oral treatment group; table 1). In the maintenance period, 
14 (12%) patients in the 4-week group, five (4%) in the 
8-week group, and nine (16%) in the oral treatment group 
Figure 2: Proportion of patients with HIV-1 RNA concentration less than 50 copies per mL (FDA snapshot algorithm) by visit in the maintenance-exposed 
population and snapshot outcomes at week 96
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Discontinued for lack of efficacy
Discontinued for other reason while below threshold
No virological data
Discontinued due to adverse event or death
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Induction period Maintenance period
Oral cabotegravir plus abacavir–lamivudine induction (maintenance-exposed population)
Intramuscular cabotegravir LA plus rilpivirine LA every 4 weeks (n=115)
Oral cabotegravir plus abacavir–lamivudine (n=56)
Intramuscular cabotegravir LA plus rilpivirine LA every 8 weeks (n=115)
withdrew from the study (figure 1). The most common 
reasons for withdrawal during the maintenance period 
were adverse events (ten patients [3%]) and withdrawn 
consent (ten patients [3%]). Eight of the ten patients who 
withdrew during the maintenance period because of 
adverse events were in the 4-week group.
During the 20-week induction period, oral treatment 
induced viral suppression (HIV-1 RNA <50 copies 
per mL) in 282 (91%) patients by day 1 (week 20 of 
induction period), with 279 (90%) patients achieving less 
than 50 copies per mL of HIV-1 RNA within the first 
8 weeks of treatment. One patient met the criteria for 
protocol-defined v irological f ailure ( two c onsecutive 
plasma HIV-1 RNA measurements ≥200 copies per mL), 
as a result of poor medication compliance, without 
experiencing treatment-emergent resistance.
Following randomisation, 108 (94%) of 115 patients 
achieved the primary efficacy en dpoint (p lasma HI V-1 
RNA <50 copies per mL; FDA snapshot algorithm) at 
week 32 in the 4-week group, 109 (95%) of 115 in the 
8-week group, and 51 (91%) of 56 in the oral treatment 
group (figure 2; appendix p 1). Both long-acting regimens 
met prespecified e fficacy cri teria for  dem onstrating 
comparability relative to the oral comparator group 
(posterior probability for comparability >90%; appendix 
p 2). Treatment differences a t w eek 3 2 f or e ach g roup 
receiving long-acting injections compared with daily oral 
treatment were 2·8% (95% CI −5·8 to 11·5) for the 4-week 
group and 3·7% (−4·8 to 12·2) for the 8-week group. At 
week 48, comparability between regimens was confirmed 
(appendix p 2), with virological suppression achieved in 
105 (91%) of 115 patients in the 4-week group, 106 (92%) 
of 115 in the 8-week group, and 50 (89%) of 56 in the oral 
treatment group (figure 2 ; a ppendix p  1 ). T hrough 
96 weeks of maintenance treatment, 100 (87%) of 
115 patients in the 4-week group, 108 (94%) of 115 in the 
8-week group, and 47 (84%) of 56 in the oral treatment 
group maintained virological suppression (figure 2 ; 
appendix p 1). Virological non-response, as defined by the 
FDA snapshot algorithm, at week 96 occurred in 
six patients (five i n t he 8 -week g roup, o ne i n t he o ral 
treatment group; figure 2). Through 96 weeks, no patients 
in the 4-week group failed for virological reasons. In 
comparison, at week 48, ten patients met virological non-
response criteria (one in the 4-week group, eight in the 
8-week group, one in the oral treatment group). For the 
8-week group, four patients with virological non-response 
at week 48 (HIV-1 RNA >50 copies per mL) were 
resuppressed with HIV-1 RNA less than 50 copies per mL 
at week 96 without a change in therapy. Of the five 
patients in the 8-week group with virological non-
response at week 96, two had HIV-1 RNA of at least 
50 copies per mL at week 96 (one of whom had HIV-1 
RNA ≥50 copies per mL at week 48), one discontinued 
due to protocol-defined v irological f ailure a t w eek 4 , 
one withdrew consent due to intolerability of injections at 
week 8, and one withdrew due to investigator discretion
at week 48 while not suppressed (and subsequently 
confirmed as a protocol-defined virological failure). One 
of the two patients with HIV-1 RNA less than 50 copies See Online for appendix
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Any event 115 (100%) 21 (18%) 115 (100%) 24 (21%) 54 (96%) 7 (13%)
Injection-site pain 112 (97%) 6 (5%) 110 (96%) 8 (7%) 0 0
Nasopharyngitis 39 (34%) 0 35 (30%) 0 22 (39%) 0
Injection-site nodule 36 (31%) 1 (<1%) 29 (25%) 1 (<1%) 0 0
Injection-site swelling 34 (30%) 0 29 (25%) 1 (<1%) 0 0
Diarrhoea 32 (28%) 0 27 (23%) 0 11 (20%) 0
Injection-site pruritus 33 (29%) 0 25 (22%) 0 0 0
Headache 27 (23%) 0 29 (25%) 1 (<1%) 14 (25%) 1 (2%)
Injection-site induration 25 (22%) 0 29 (25%) 1 (<1%) 0 0
Injection-site warmth 21 (18%) 0 23 (20%) 1 (<1%) 0 0
Upper respiratory tract 
infection
13 (11%) 0 23 (20%) 0 7 (13%) 0
Injection-site bruising 14 (12%) 0 20 (17%) 0 0 0
Nausea 18 (16%) 0 16 (14%) 0 9 (16%) 0
Injection-site erythema 19 (17%) 0 13 (11%) 1 (<1%) 0 0
Pyrexia 16 (14%) 0 16 (14%) 0 3 (5%) 0
Gastroenteritis 15 (13%) 0 14 (12%) 0 6 (11%) 1 (2%)
Fatigue 14 (12%) 0 14 (12%) 0 4 (7%) 0
Syphilis 11 (10%) 0 17 (15%) 0 6 (11%) 0
Back pain 13 (11%) 0 15 (13%) 0 10 (18%) 0
Insomnia 13 (11%) 0 12 (10%) 0 4 (7%) 0
Bronchitis 12 (10%) 1 (<1%) 12 (10%) 0 6 (11%) 0
Cough 13 (11%) 0 11 (10%) 0 7 (13%) 0
Influenza 16 (14%) 0 6 (5%) 0 2 (4%) 0
Arthralgia 10 (9%) 0 12 (10%) 0 4 (7%) 0
Anogenital warts 11 (10%) 0 9 (8%) 0 2 (4%) 0
Pharyngitis 8 (7%) 0 12 (10%) 0 5 (9%) 0
Respiratory tract infection 11 (10%) 0 6 (5%) 0 6 (11%) 0
Asthenia 10 (9%) 0 7 (6%) 0 9 (16%) 0
Treatment-related adverse events*
Any event 113 (98%) 10 (9%) 110 (96%) 10 (9%) 21 (38%) 1 (2%)
Injection-site pain 112 (97%) 6 (5%) 109 (95%) 8 (7%) 0 0
Injection-site nodule 35 (30%) 1 (<1%) 29 (25%) 1 (<1%) 0 0
Injection-site swelling 34 (30%) 0 29 (25%) 1 (<1%) 0 0
Injection-site pruritus 33 (29%) 0 24 (21%) 0 0 0
Injection-site induration 25 (22%) 0 28 (24%) 1 (<1%) 0 0
Injection-site warmth 21 (18%) 0 22 (19%) 1 (<1%) 0 0
Injection-site bruising 14 (12%) 0 19 (17%) 0 0 0
Injection-site erythema 19 (17%) 0 12 (10%) 1 (<1%) 0 0
Nausea 12 (10%) 0 8 (7%) 0 5 (9%) 0
Headache 7 (6%) 0 6 (5%) 0 4 (7%) 0
Pyrexia 7 (6%) 0 5 (4%) 0 0 0
(Table 2 continues on next page)
per mL at week 96 remained on the study and had HIV-1 
concentrations less than 50 copies per mL at the next 
scheduled visit. The patient in the 4-week group with 
virological non-response at week 48 (HIV-1 RNA, 
59 copies per mL) remained on the study beyond week 48 
and had subsequent viral resuppression with HIV-1 RNA 
less than 50 copies per mL at week 96. The virological 
non-responder in the oral treatment group discontinued 
as a result of protocol-defined virological failure at week 8.
Three patients (two in the 8-week group, [week 4 and 
week 48], one in the oral treatment group [week 8]) met 
the criteria for protocol-defined virological failure 
through week 96. Viral genotyping analysis for the 
patient in the oral treatment group had no treatment-
emergent resistance mutations in the genes encoding 
viral reverse transcriptase, protease, or integrase. Of the 
two patients in the 8-week group, a mixture emerged for 
one at integrase codon 269 (R269R/G), which did not 
decrease cabotegravir susceptibility. The second patient 
harboured virus with treatment-emergent reverse 
transcriptase mutations K103N, E138G, and K238T, with 
phenotypic resistance to efavirenz, rilpivirine, and 
nevirapine, and an integrase mutation Q148R, with 
phenotypic resistance to raltegravir, elvitegravir, and 
cabotegravir, while remaining sensitive to dolutegravir.
Most patients in all groups maintained HIV-1 RNA less 
than 200 copies per mL (100 [87%] in the 4-week group, 
110 [96%] in the 8-week group, and 47 [84%] in the oral 
treatment group). The mean change from baseline in 
plasma HIV-1 RNA concentration was –2·89 log10 copies 
per mL (SD 0·713) for patients in the 4-week group, 
–2·77 log10 copies per mL (0·602) in the 8-week group,
and –2·77 log10 copies per mL (0·582) in the oral treatment
group. At week 96 of the maintenance period, CD4+ cell
counts increased from the beginning of the induction
period by a median of 226 cells per mm³ (IQR 145–393) in 
the 4-week group (n=100), 239 cells per mm³ (111–359) in 
the 8-week group (n=109), and 317 cells per mm³ (214–505) 
in the oral treatment group (n=47).
During the induction and maintenance period, in the 
maintenance-exposed population, total adverse events of 
any grade and attribution occurred in 115 (100%) patients 
in the 4-week group, 115 (100%) in the 8-week group, and 
54 (96%) in the oral treatment group (table 2). Injection-
site pain, the most common injection-site reaction, was 
the most frequently reported adverse event in the 
intramuscular groups (112 [97%] patients in the 4-week 
group, 110 [96%] patients in the 8-week group). Most 
injection-site reactions were mild (grade 1; 3648 [84%] of 
4360 injections) or moderate (grade 2; 673 [15%] of 4360 
injections) in intensity, with median symptom duration 
of 3 days (appendix p 3). The most commonly reported 
adverse events other than an injection-site reaction were 
nasopharyngitis (39 patients [34%] in the 4-week group, 
35 [30%] in the 8-week group, and 22 [39%] in the oral 
treatment group), diarrhoea (32 [28%] in the 4-week 
group, 27 [23%] in the 8-week group, and 11 [20%] in the 
oral treatment group), and headache (27 [23%] in the 
4-week group, 29 [25%] in the 8-week group, 14 [25%] in
the oral treatment group). Serious adverse events
occurred in 13 (11%) patients in each of the intramuscular 
treatment groups and nine (16%) patients in the oral
treatment group, only one of which was drug related
(migraine, which occurred in the initial oral induction
period of the study). During the maintenance period,
serious adverse events occurred in 11 (10%) patients in
each of the intramuscular groups compared with
seven patients (13%) in the oral treatment group.
However, none was considered to be related to study
treatment. 11 patients (4%) developed an adverse event
during the maintenance period, which led to withdrawal:
eight patients (7%) in the 4-week group, two (2%) in the
8-week group, and one (2%) in the oral treatment group.
Two patients (both in the 8-week group) had injection-
site reactions leading to withdrawal within 8 weeks of
initiating dosing. Two deaths occurred during the study:
one resulted from a motor vehicle accident that occurred
in the initial oral induction period of the study, and the
second occurred after an epileptic seizure in a patient in
the 4-week intramuscular treatment group who had
received 48 weeks of cabotegravir and 32 weeks of
rilpivirine treatment. The seizure event was not
considered likely to be related to cabotegravir or
rilpivirine on the basis of the late time to onset of
symptoms and both direct and circumstantial evidence
of recreational drug use proximal to the event.
Progression of HIV disease was uncommon. One 
patient in the 4-week group experienced disease 
progression from Centers for Disease Control and 
Prevention (CDC) Class A to death (epileptic seizure). 
Four patients in the 8-week group experienced disease 
progression from CDC Class A to Class C (one had 
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(Continued from previous page)
Injection-site 
discolouration
6 (5%) 0 3 (3%) 0 0 0
Dyspepsia 6 (5%) 0 1 (<1%) 0 1 (2%) 0
Asthenia 3 (3%) 0 2 (2%) 0 3 (5%) 0
Data are n (%). LA=long-acting. *Includes all post-baseline induction period and maintenance period adverse events, 
as well as long-term follow-up period adverse events for patients withdrawing from intramuscular dosing that 
occurred within 35 or 63 days (4-week group or 8-week group) of the last maintenance period intramuscular injection 
until up to and including the start date of the long-term follow-up period on oral highly active antiretroviral treatment. 
†At least 10% in any treatment group for total adverse events and at least 5% in any treatment group for 
treatment-related adverse events. ‡Includes only events listed in the grade 1–4 column; other grade 3–4 events that 
did not meet the 5% or 10% cutoff for the grade 1–4 column are not shown.
Table 2: Summary of total adverse events and treatment-related adverse events through week 96 in the 
safety maintenance population
Kaposi’s sarcoma, one had pneumonia, and two had 
herpes simplex). No patient experienced disease 
progression to CDC Class C or death in the oral 
treatment group.
Grade 3 or more severe maintenance period treatment-
emergent laboratory abnormalities occurred in 32 patients 
(28%) in the 4-week group, 21 (18%) in the 8-week group, 
and 12 (21%) in the oral treatment group. Grade 3 or more 
severe maintenance period treatment-emergent ALT 
elevations occurred in four (3%) patients in each of the 
4-week and 8-week groups, and in three (5%) patients
receiving oral treatment, largely attributable to acute
hepatitis C infections. Among patients meeting pre-
defined liver stopping criteria, possible drug-induced
liver injury occurred in two patients (both treated with
oral cabotegravir plus abacavir–lamivudine; one during
the induction period [before randomisation], and one
during the maintenance period). In both cases, liver
chemistry abnormalities resolved following treatment
discontinuation, and the patients remained clinically
asymptomatic. Mean change from baseline was evaluated
across all laboratory parameters, and no clinically
significant differences were observed through 96 weeks.
At week 48, cabotegravir geometric mean trough 
concentrations (C0; 95% CI) were 2·58 μg/mL (2·4–2·8) 
for the 4-week group, 1·46 μg/mL (1·3–1·6) for the 
8-week group, and 4·47 μg/mL (3·9–5·2) for the oral 
treatment group, which were 16 times, nine times, and 
27 times greater than the in-vitro protein-adjusted 
90% inhibitory concentration (PA-IC90) of 0·166 μg/mL 
against wild-type HIV-1. For rilpivirine, week 48 
geometric mean C0 (95% CI) values were 94·64 ng/mL
(86·6–103·4) for the 4-week group and 64·48 ng/mL 
(60·0–69·3) for the 8-week group, which were 
eight times and five times greater than in-vitro PA-IC90 of 
12 ng/mL against wild-type HIV-1. Accumulation of 
rilpivirine was observed through 24–48 weeks of dosing, 
with the lowest rilpivirine trough concentrations 
observed after initial intramuscular injections in both 
groups (figure 3). No relationship was observed between 
cabotegravir concentrations and virological non-
response at week 48. In a post-hoc analysis of seven of 
the nine patients in the 8-week group with virological 
non-response at week 48 (FDA snapshot algorithm), 
rilpivirine trough concentrations at week 48 (or last 
available trough concentration before week 48) were in 
the lowest 25th quartile among all rilpivirine samples, 
whereas cabotegravir trough concentrations were 
distributed throughout the quartile ranges. Of the 
two patients in the 8-week group with protocol-defined 
virological failure during the maintenance period 
through week 48, one patient had non-quantifiable 
rilpivirine concentration 4 weeks post injection without 
treatment-emergent resistance; there was no clear 
correlation between cabotegravir or rilpivirine 
concentrations at the time of viral rebound with the 
other patient.
High levels of treatment satisfaction were observed 
across all treatment groups (figure 4). At week 96, patients 
reported very high levels of satisfaction across all three 
groups (4-week, 8-week, and oral treatment, via the 
HIVTSQ[s]), with 246 (97%) of 254 patients selecting a 
score of 5 or 6 on a 6-point satisfaction scale. A similar 






























































1 24 3228 4036164 44 481280 20
Week number
B
Intramuscular cabotegravir LA plus rilpivirine LA every 4 weeks
Intramuscular cabotegravir LA plus rilpivirine LA every 8 weeks
PA-IC90
10 mg orally Cτ
30 mg orally Cτ
Intramuscular cabotegravir LA plus rilpivirine LA every 4 weeks
Intramuscular cabotegravir LA plus rilpivirine LA every 8 weeks
PA-IC90
25 mg orally Cτ
Figure 3: Arithmetic mean (SD) plasma concentration–time profiles following every 4 weeks and every 8 weeks administration of (A) cabotegravir LA and (B) rilpivirine LA through week 48
Cτ=concentration at the end of dosing interval. LA=long-acting. PA-IC90=protein-adjusted 90% inhibitory concentration.
(≥99%; 99 of 100 in the 4-week group and 107 of 108 in the 
8-week group) reported they would be highly satisfied to
continue their current long-acting regimen, while a lower
percentage would elect to continue on oral dosing (78%;
36 of 46 patients in the oral treatment group). Patients
who discontinued for any reason before week 96 did not
complete the questionnaire at this timepoint, introducing
a small degree of selection bias in these results.
Discussion
LATTE-2 is the first study to analyse the efficacy and 
safety of fully injectable two-drug long-acting ART 
regimens in patients with HIV-1 infection and contributes 
to the growing number of studies evaluating simplification 
to two-drug therapy. Both the long-acting injectable 
4-week and 8-week regimens maintained virological
suppression at rates comparable to oral daily three-drug
ART, with two protocol-defined virological failures
occurring among the 230 patients who received long-
acting therapy during the 96-week maintenance period.
The long-acting cabotegravir plus rilpivirine regimens
were generally well tolerated, with no drug-related serious 
adverse events and few adverse event-related withdrawals.
Although injection-site reactions were common, they
Figure 4: Summary of patient-reported outcomes at (A) week 48 (maintenance treatment) and (B) week 96

































































How satisfied would you be to continue with your present form of 
treatment?




























How satisfied would you be to continue with your present form of 
treatment?
Intramuscular cabotegravir LA plus rilpivirine LA Intramuscular cabotegravir LA plus rilpivirine LA
6 5 4 3 2 1 0
Very satisfied Very dissatisfied
6 5 4 3 2 1 0
Very satisfied Very dissatisfied
were transient in nature, mild or moderate in severity, 
and did not appear to compromise high levels of patient-
reported satisfaction. The long-term acceptability of 
administering chronic intra muscular injections to 
patients was also shown in LATTE-2, with very few 
withdrawals resulting from injection-site reactions, 
two patients (<1%) through 96 weeks.
Treatment with the 4-week and 8-week regimens 
maintained virological suppression in 87% (n=100) and 
94% (n=108) of patients, respectively, compared with 
84% (n=47) of patients treated with oral cabotegravir plus 
abacavir–lamivudine. These proportions are consistent 
with multiple other studies examining efficacy of  
switching oral regimens in patients with viral 
suppression.19–21 The LATTE-2 study was unique compared 
with previous switch studies in its evaluation of short-
term viral suppression, before dosing simplification. Few 
virological non-responders, as determined by the 
stringent FDA snapshot algorithm, were observed with 
either long-acting regimen in the LATTE-2 study, with a 
higher rate of non-response observed in the 8-week group 
(five patients [4%]) than in the 4-week group (none). Only 
two patients in the 8-week group, and none in the 4-week 
group, met the criteria for protocol-defined v irological 
failure. One participant had emergence of well described 
NNRTI and INSTI mutations that conferred reduced 
susceptibility. No NNRTI mutations were observed in the 
second participant, who had undetectable rilpivirine 
concentrations, and a mixture emerged at an integrase 
codon not associated with INSTI resistance22 with no 
change in cabotegravir susceptibility. The lack of 
virological non-responders in the 4-week regimen has led 
to the selection of an optimised 4-week dosing regimen in 
the ongoing phase 3 clinical programme, while the 
week 96 data provide supportive evidence for the long-
term durable response of both the 4-week and 8-week 
dosing options, supporting further investigation of both 
dosing intervals.
One of the challenges of injectable long-acting agents 
is the potential for serious systemic adverse events 
without the possibility to curtail exposure to the agent. 
The LATTE-2 study implemented a period of cabotegravir 
and rilpivirine oral dosing, before long-acting 
cabotegravir or rilpivirine dosing, as a strategy to identify 
any early-onset acute safety issues before giving the long-
acting injectable formulations. No drug hypersensitivity 
reactions were observed in the LATTE-2 study. An oral 
lead-in strategy has been implemented in phase 3 HIV 
treatment studies, to determine if there is a need for 
continued use of the oral lead-in.
The high satisfaction reported by patients in the 
LATTE-2 study suggests that long-acting regimens might 
provide a preferred alternative to oral daily therapy for 
patients infected with HIV.23,24 The acceptability and 
tolerability of injectable dosing options will be an 
important component of long-term treatment success, 
and a high degree of treatment satisfaction will avail this 
option for patients burdened by life-long daily oral 
medication compliance.
This study has some limitations. Although the LATTE-2 
study population included patients from five countries, 
participants were predominantly male and were 
restricted at entry to CD4+ cell count of at least 200 cells 
per mm³, which does not accurately represent the global 
HIV-infected population.1 Therefore, the efficacy, 
safety, and pharmacokinetic outcomes of long-acting 
cabotegravir plus rilpivirine in different subpopulations 
infected with HIV-1 needs further evaluation. 
Additionally, LATTE-2 was an open-label study, and 
cabotegravir was included in both the intramuscular and 
oral comparator group, possibly influencing adverse 
event reporting and limiting adverse event comparisons 
relative to other, standard-of-care ART. Lastly, treatment 
satisfaction data from clinical trial participants, who 
entered the study with an 80% chance of receiving long-
acting treatment might not be generalisable to a more 
diverse population of patients with HIV-1.
Results from the LATTE-2 study show high rates of 
efficacy and an acceptable safety profile for long-acting 
cabotegravir plus rilpivirine as injectable two-drug 
maintenance therapy in virologically suppressed patients 
with HIV. These results support the further evaluation of 
monthly long-acting cabotegravir plus rilpivirine as the 
first all-injectable ART regimen.
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